Hany Elmariah, MD, discussed the safety profile of fedratinib and its evolving role in the post-transplant setting for patients with myeloproliferative neoplasms.
NKGen takes a meaningful step towards potential treatment for frontotemporal dementia (“FTD”) patients with limited treatment options.SANTA ANA, Calif., Feb. 21, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech ...
Omeros (OMER) announced statistical analysis results related to the expanded access program for narsoplimab, Omeros’ ...
Shares of Century Therapeutics, Inc. (NASDAQ:IPSC – Get Free Report) have received a consensus recommendation of “Buy” from ...
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell products for cancer and autoimmune disease. Led by a ...
The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem ...
Adding engineered human blood vessel-forming cells to islet transplants boosted the survival of the insulin-producing cells ...
A combination of mRNA and a new lipid nanoparticle could help heal damaged lungs, according to new research from the Perelman ...
Doctors harvest stem cells from the patient’s bone marrow and then send them off to a lab, where CRISPR is used to turn up the production of another, functional version of haemoglobin. This version is ...
There are multiple chapters near you. Select your preferred chapter.
Fred Hutch’s Phase 2 study among blood cancer patients is a “gamechanger” in preventing graft-versus-host disease after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback